120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
心肌肌钙蛋白I在评估乳腺癌术后患者蒽环类药物诱导心脏毒性中的临床价值
Received 10 November 2025
Accepted for publication 14 January 2026
Published 23 January 2026 Volume 2026:18 580515
DOI https://doi.org/10.2147/BCTT.S580515
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pranela Rameshwar
Hui Li,1 Xiaoxiong Li,2 Sijia Tang2
1Department of Oncology Medicine, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 2Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China
Correspondence: Sijia Tang, Email ty1374929045@163.com
Objective: To investigate the clinical value of high-sensitivity cardiac troponin I (hs-cTnI) in evaluating chemotherapy-related cardiac dysfunction (CTRCD) induced by anthracyclines in postoperative breast cancer patients.
Methods: A retrospective study was conducted including 180 postoperative breast cancer patients treated at our hospital from August 2021 to August 2024. All patients completed six cycles of the cyclophosphamide–epirubicin–fluorouracil (CEF) regimen. According to the Chinese Society of Clinical Oncology (CSCO) guideline criteria, patients were divided into a cardiotoxicity group (n = 50) and a non-cardiotoxicity group (n = 130). Serum hs-cTnI and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, as well as left ventricular ejection fraction (LVEF) measured by echocardiography, were dynamically monitored before chemotherapy (T0) and after each chemotherapy cycle (T1–T6). The predictive value of each marker for CTRCD was evaluated using receiver operating characteristic (ROC) curves.
Results: Compared with the non-cardiotoxicity group, the cardiotoxicity group showed significantly higher serum hs-cTnI and NT-proBNP levels from T1 onward, with progressive increases over chemotherapy cycles (P < 0.01), while LVEF progressively decreased (P < 0.01). ROC analysis indicated that serum hs-cTnI at the third chemotherapy cycle (T3) had an area under the curve (AUC) of 0.957 (95% CI: 0.905– 0.988) for predicting CTRCD, with an optimal cutoff value of > 1358.5 pg/mL, yielding a sensitivity of 92.00% and specificity of 91.54%. Its predictive performance was significantly superior to that of NT-proBNP at the same time point [AUC = 0.684 (95% CI: 0.590– 0.763)].
Conclusion: Serum hs-cTnI is a highly sensitive and specific biomarker for the early and dynamic monitoring of anthracycline-induced cardiotoxicity. The hs-cTnI level at mid-chemotherapy (third cycle) has excellent predictive value for CTRCD, facilitating early identification of high-risk patients and timely clinical intervention.
Keywords: breast cancer, anthracyclines, chemotherapy, cardiotoxicity, cardiac troponin I, high-sensitivity cardiac troponin I
1Department of Oncology Medicine, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 2Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China
Correspondence: Sijia Tang, Email ty1374929045@163.com
Objective: To investigate the clinical value of high-sensitivity cardiac troponin I (hs-cTnI) in evaluating chemotherapy-related cardiac dysfunction (CTRCD) induced by anthracyclines in postoperative breast cancer patients.
Methods: A retrospective study was conducted including 180 postoperative breast cancer patients treated at our hospital from August 2021 to August 2024. All patients completed six cycles of the cyclophosphamide–epirubicin–fluorouracil (CEF) regimen. According to the Chinese Society of Clinical Oncology (CSCO) guideline criteria, patients were divided into a cardiotoxicity group (n = 50) and a non-cardiotoxicity group (n = 130). Serum hs-cTnI and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, as well as left ventricular ejection fraction (LVEF) measured by echocardiography, were dynamically monitored before chemotherapy (T0) and after each chemotherapy cycle (T1–T6). The predictive value of each marker for CTRCD was evaluated using receiver operating characteristic (ROC) curves.
Results: Compared with the non-cardiotoxicity group, the cardiotoxicity group showed significantly higher serum hs-cTnI and NT-proBNP levels from T1 onward, with progressive increases over chemotherapy cycles (P < 0.01), while LVEF progressively decreased (P < 0.01). ROC analysis indicated that serum hs-cTnI at the third chemotherapy cycle (T3) had an area under the curve (AUC) of 0.957 (95% CI: 0.905– 0.988) for predicting CTRCD, with an optimal cutoff value of > 1358.5 pg/mL, yielding a sensitivity of 92.00% and specificity of 91.54%. Its predictive performance was significantly superior to that of NT-proBNP at the same time point [AUC = 0.684 (95% CI: 0.590– 0.763)].
Conclusion: Serum hs-cTnI is a highly sensitive and specific biomarker for the early and dynamic monitoring of anthracycline-induced cardiotoxicity. The hs-cTnI level at mid-chemotherapy (third cycle) has excellent predictive value for CTRCD, facilitating early identification of high-risk patients and timely clinical intervention.
Keywords: breast cancer, anthracyclines, chemotherapy, cardiotoxicity, cardiac troponin I, high-sensitivity cardiac troponin I